<?xml version="1.0" encoding="UTF-8"?>
<document id="28684402">
	<sentence id="s1" text="Initial antitumoral responses are often seen, but drug-resistant clones with reactivation of the MEK-angiogenesis pathway soon appear.">
		<entity id="s1.e1" charOffset="12-17"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s1.e2" charOffset="101-113"
			type="GO" text="angiogenesis" ontology_id="GO_0001525"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
	</sentence>
	<sentence id="s2" text="To elucidate the possible functions of EVs in protein phosphorylation-mutant melanoma, we determined the RNA content of the EVs, including apoptotic bodies, microvesicles, and exosomes, released from such cancer cells after vemurafenib treatment.">
		<entity id="s2.e1" charOffset="46-69"
			type="GO" text="protein phosphorylation" ontology_id="GO_0006468"/>
		<entity id="s2.e2" charOffset="205-211"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="true"/>
	</sentence>
	<sentence id="s3" text="RNA sequencing and quantitative PCR show that cells and EVs from vemurafenib-treated cell cultures and tumor tissues harvested from cell-derived and patient-derived xenografts harbor unique protein polyubiquitinationNAs, especially increased expression of miR-211-5p.">
		<entity id="s3.e1" charOffset="103-108"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s3.e2" charOffset="190-216"
			type="GO" text="protein polyubiquitination" ontology_id="GO_0000209"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e2" pgr="false"/>
	</sentence>
</document>
